Nifty
:
23897.70
Sensex
:
76515.43
24.25 (0.10%)
362.57 (0.48%)
Nifty
Sensex
:
:
23897.70
76515.43
24.25 (0.10%)
362.57 (0.48%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 500257 | NSE: LUPIN

NSE BSE
2110.00
04-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2140.1
  •  2148
  •  2100.6
  •  2132.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  862828
  •  1826614866.7
  •  2529.5
  •  1900

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 96,528.82
  • 17.66
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 96,786.12
  • 0.85%
  • 4.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.85%
  • 0.34%
  • 5.06%
  • FII
  • DII
  • Others
  • 22.42%
  • 21.77%
  • 3.56%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.80
  • 11.25
  • 11.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.15
  • 106.89
  • 16.58

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.63
  • -
  • 40.70

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.44
  • 26.79
  • 32.80

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.83
  • 4.30
  • 5.24

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.43
  • 17.01
  • 17.86

Earnings Forecasts:

(Updated: 29-08-2026)
Description
2026
2027
2028
2029
Adj EPS
84
-4
-4.4
111.25
P/E Ratio
24.99
-524.70
-477.00
18.87
Revenue
23.88
23.6
20.3
27099.9
EBITDA
29724.6
31328.7
34378.6
7618.3
Net Income
7529.52
7567.75
8759.3
5085.28
ROA
4580.49
4668.86
5450.31
16.72
P/B Ratio
-0.42
-0.26
-0.23
4.46
ROE
4.19
3.63
3.19
25.98
FCFF
18.62
16.52
16.45
2951.41
FCFF Yield
3149.24
4443.42
6368
2.75
Net Debt
2.94
4.15
5.94
-1017.3
BVPS
-5038.83
-8049.19
-8997.37
471.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
8,276.89
6,268.34
32.04%
7,474.66
5,667.13
31.89%
7,167.52
5,767.71
24.27%
7,047.51
5,672.73
24.23%
Expenses
5,827.34
4,541.10
28.32%
4,989.08
4,345.96
14.80%
4,905.67
4,411.81
11.19%
4,706.18
4,332.37
8.63%
EBITDA
2,449.55
1,727.24
41.82%
2,485.58
1,321.17
88.13%
2,261.85
1,355.90
66.82%
2,341.33
1,340.36
74.68%
EBIDTM
29.60%
27.55%
33.25%
23.31%
31.56%
23.51%
33.22%
23.63%
Other Income
130.32
79.04
64.88%
140.71
56.95
147.08%
114.70
53.71
113.55%
90.00
42.29
112.82%
Interest
109.64
91.76
19.49%
120.16
89.10
34.86%
114.98
66.89
71.89%
107.59
70.87
51.81%
Depreciation
452.85
298.98
51.46%
446.79
393.18
13.63%
312.96
271.45
15.29%
316.77
256.92
23.30%
PBT
2,017.38
1,415.54
42.52%
1,928.00
895.84
115.22%
1,522.04
1,071.27
42.08%
2,006.97
1,054.86
90.26%
Tax
600.38
194.08
209.35%
459.33
113.46
304.84%
341.53
212.41
60.79%
522.14
195.38
167.24%
PAT
1,417.00
1,221.46
16.01%
1,468.67
782.38
87.72%
1,180.51
858.86
37.45%
1,484.83
859.48
72.76%
PATM
17.12%
19.49%
19.65%
13.81%
16.47%
14.89%
21.07%
15.15%
EPS
30.95
26.69
15.96%
31.94
16.92
88.77%
25.73
18.74
37.30%
32.35
18.69
73.09%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
29,966.58
27,958.03
22,707.90
20,010.82
16,641.66
16,405.48
15,162.96
15,374.76
14,664.56
15,804.15
17,494.33
Net Sales Growth
28.19%
23.12%
13.48%
20.25%
1.44%
8.19%
-1.38%
4.84%
-7.21%
-9.66%
 
Cost Of Goods Sold
7,643.77
6,325.59
5,818.18
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
Gross Profit
22,322.81
21,632.44
16,889.72
14,366.16
10,617.77
10,624.64
10,308.68
10,412.04
10,227.89
11,070.39
12,833.36
GP Margin
74.49%
77.37%
74.38%
71.79%
63.80%
64.76%
67.99%
67.72%
69.75%
70.05%
73.36%
Total Expenditure
20,428.27
19,798.50
17,430.38
16,221.71
14,921.09
16,190.24
12,596.08
13,019.96
12,103.84
12,656.64
13,001.19
Power & Fuel Cost
-
461.55
479.09
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
% Of Sales
-
1.65%
2.11%
2.46%
2.88%
2.71%
2.73%
2.88%
3.02%
2.75%
2.16%
Employee Cost
-
4,574.53
3,964.20
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
% Of Sales
-
16.36%
17.46%
17.46%
18.55%
18.22%
18.64%
19.43%
18.89%
18.13%
16.29%
Manufacturing Exp.
-
3,343.42
3,006.40
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
% Of Sales
-
11.96%
13.24%
13.68%
13.08%
13.34%
12.83%
12.05%
11.81%
13.21%
12.98%
General & Admin Exp.
-
2,931.35
2,514.00
2,221.05
1,733.07
3,490.62
1,218.42
1,456.46
1,324.00
1,223.28
1,509.56
% Of Sales
-
10.48%
11.07%
11.10%
10.41%
21.28%
8.04%
9.47%
9.03%
7.74%
8.63%
Selling & Distn. Exp.
-
1,853.97
1,417.19
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,147.29
1,049.48
% Of Sales
-
6.63%
6.24%
6.71%
7.14%
6.68%
6.77%
7.03%
8.23%
7.26%
6.00%
Miscellaneous Exp.
-
308.09
231.32
286.67
232.45
201.43
310.93
238.11
192.55
166.20
1,049.48
% Of Sales
-
1.10%
1.02%
1.43%
1.40%
1.23%
2.05%
1.55%
1.31%
1.05%
1.62%
EBITDA
9,538.31
8,159.53
5,277.52
3,789.11
1,720.57
215.24
2,566.88
2,354.80
2,560.72
3,147.51
4,493.14
EBITDA Margin
31.83%
29.18%
23.24%
18.94%
10.34%
1.31%
16.93%
15.32%
17.46%
19.92%
25.68%
Other Income
475.73
1,080.92
201.61
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
Interest
452.37
434.49
294.87
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
Depreciation
1,529.37
1,375.50
1,169.26
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
PBT
7,474.39
7,430.46
4,015.00
2,422.27
716.49
-1,372.57
1,675.12
1,505.36
1,745.19
2,007.64
3,534.89
Tax
1,923.38
1,517.08
708.74
486.70
268.80
137.15
448.52
1,157.11
887.94
288.46
978.51
Tax Rate
25.73%
22.07%
17.65%
20.09%
37.52%
-9.99%
26.78%
153.61%
63.19%
53.10%
27.68%
PAT
5,551.01
5,332.84
3,281.62
1,914.48
430.08
-1,528.04
1,216.53
-399.49
512.09
251.26
2,557.46
PAT before Minority Interest
5,528.83
5,355.47
3,306.26
1,935.57
447.69
-1,509.36
1,227.93
-399.88
521.02
258.35
2,564.63
Minority Interest
-22.18
-22.63
-24.64
-21.09
-17.61
-18.68
-11.40
0.39
-8.93
-7.09
-7.17
PAT Margin
18.52%
19.07%
14.45%
9.57%
2.58%
-9.31%
8.02%
-2.60%
3.49%
1.59%
14.62%
PAT Growth
49.13%
62.51%
71.41%
345.15%
-
-
-
-
103.81%
-90.18%
 
EPS
121.41
116.64
71.78
41.87
9.41
-33.42
26.61
-8.74
11.20
5.50
55.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
22,448.27
17,203.50
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
Share Capital
91.44
91.32
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
Total Reserves
22,292.63
17,028.20
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
Non-Current Liabilities
2,635.50
2,390.04
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
Secured Loans
1,327.35
1,196.48
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
Unsecured Loans
316.04
569.75
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
Long Term Provisions
532.70
436.08
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
Current Liabilities
12,651.24
8,961.39
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
Trade Payables
4,173.13
2,958.16
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
Other Current Liabilities
3,300.05
2,274.32
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
Short Term Borrowings
3,948.78
3,015.56
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
Short Term Provisions
1,229.28
713.35
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
Total Liabilities
37,800.11
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
Net Block
10,993.88
9,719.35
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
Gross Block
23,217.39
20,183.69
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
Accumulated Depreciation
12,137.78
10,464.34
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
Non Current Assets
13,772.73
11,847.20
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
Capital Work in Progress
1,016.11
516.64
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
Non Current Investment
92.54
87.27
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
Long Term Loans & Adv.
301.79
307.83
320.65
620.92
572.41
405.79
409.58
402.61
383.00
950.76
Other Non Current Assets
1,368.41
1,216.11
47.82
57.70
15.90
12.98
72.95
47.13
9.38
7.96
Current Assets
24,027.38
16,798.58
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,200.94
11,952.93
Current Investments
3,577.13
1,059.11
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
Inventories
6,083.25
5,476.35
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
Sundry Debtors
6,604.06
5,497.10
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
Cash & Bank
5,652.90
3,142.33
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
Other Current Assets
2,110.04
1,311.06
1,428.05
1,519.98
1,644.48
1,300.77
1,717.86
1,769.95
1,703.35
1,191.01
Short Term Loans & Adv.
439.70
312.63
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
Net Current Assets
11,376.14
7,837.19
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,105.39
5,832.34
Total Assets
37,800.11
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,580.22
26,099.64

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
7,334.50
2,999.94
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
PBT
6,872.55
4,015.00
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
Adjustment
1,095.61
1,301.52
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
Changes in Working Capital
633.69
-1,410.54
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
Cash after chg. in Working capital
8,601.85
3,905.98
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,267.35
-906.04
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-3,864.59
-4,171.89
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
Net Fixed Assets
-615.06
-900.14
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
Net Investments
-3,670.29
-374.36
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
Others
420.76
-2,897.39
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
Cash from Financing Activity
-845.87
1,731.88
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
Net Cash Inflow / Outflow
2,624.04
559.93
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
Opening Cash & Equivalents
1,543.69
983.76
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
Closing Cash & Equivalent
4,167.73
1,543.69
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
489.59
374.93
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
ROA
16.12%
12.63%
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
ROE
27.11%
21.13%
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
ROCE
28.86%
21.97%
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
Fixed Asset Turnover
1.99
1.87
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
Receivable days
51.23
50.00
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
Inventory Days
48.93
51.19
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
Payable days
205.75
185.58
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
Cash Conversion Cycle
-105.59
-84.38
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
Total Debt/Equity
0.26
0.30
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
Interest Cover
16.82
14.62
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017

News Update:


  • Lupin gets USFDA’s final nod for Pitolisant Tablets
    17th Aug 2026, 14:51 PM

    The USFDA has approved the company’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labeling

    Read More
  • Lupin gets USFDA’s nod for Sodium Zirconium Cyclosilicate for Oral Suspension in US
    10th Aug 2026, 18:14 PM

    Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma) had estimated annual sales of $568 million in the U.S

    Read More
  • Lupin reports 16% rise in Q1 consolidated net profit
    7th Aug 2026, 11:19 AM

    Consolidated total income of the company increased by 32.45% to Rs 8,407.21 crore for Q1FY27

    Read More
  • Lupin launches Sugammadex Injection in United States
    31st Jul 2026, 13:05 PM

    The company’s Sugammadex Injection is the bioequivalent to Bridion Injection of Merck, Sharp & Dohme LLC

    Read More
  • Lupin gets EIR from USFDA for Somerset facility
    2nd Jul 2026, 09:20 AM

    The inspection was conducted from April 13, 2026, to April 17, 2026

    Read More
  • Lupin gets USFDA’s tentative approval for Enzalutamide Tablets
    27th Jun 2026, 17:28 PM

    Lupin’s tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.

    Read More
  • Lupin launches Azilsartan Medoxomil tablets in United States
    18th Jun 2026, 09:28 AM

    Azilsartan Medoxomil Tablets (RLD Edarbi) had estimated annual sales of $53.5 million in the U.S.

    Read More
  • Lupin partners with ERN for launch of Luforbec in Spain
    8th Jun 2026, 14:11 PM

    This collaboration combines the company’s global respiratory expertise and proven pMDI manufacturing excellence and ERN’s robust national reach

    Read More
  • Lupin gets UDFDA approval for Ranluspec (ranibizumab) injection
    5th Jun 2026, 09:07 AM

    Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and PFS

    Read More
  • Lupin, Natco get USFDA’s nod for Eribulin Mesylate Injection
    3rd Jun 2026, 12:12 PM

    Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials is the bioequivalent to the RLD Halaven Injection of Eisai, Inc

    Read More
  • Lupin gets USFDA nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets
    30th May 2026, 10:58 AM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin gets Establishment Inspection Report for Ankleshwar facility
    28th May 2026, 13:00 PM

    The EIR has been issued following the closure of a product-specific Pre-Approval Inspection conducted by USFDA

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.